Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance
by Jessica Moore · The Cerbat GemRepligen (NASDAQ:RGEN – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.970-2.050 for the period, compared to the consensus earnings per share estimate of 1.970. The company issued revenue guidance of $803.0 million-$833.0 million, compared to the consensus revenue estimate of $827.9 million.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on RGEN. UBS Group decreased their target price on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. HC Wainwright boosted their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Finally, Canaccord Genuity Group reduced their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $170.25.
View Our Latest Analysis on RGEN
Repligen Stock Performance
Shares of Repligen stock traded up $7.14 during trading hours on Tuesday, hitting $125.35. 1,188,935 shares of the company were exchanged, compared to its average volume of 870,858. The business has a 50-day moving average of $121.56 and a 200-day moving average of $144.68. The stock has a market capitalization of $7.07 billion, a price-to-earnings ratio of 147.21, a P/E/G ratio of 2.28 and a beta of 1.09. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. Repligen has a 1 year low of $109.50 and a 1 year high of $175.77.
Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.Repligen’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts expect that Repligen will post 1.97 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. Compound Planning Inc. purchased a new position in Repligen in the fourth quarter worth $204,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Repligen in the fourth quarter valued at $204,000. Polar Capital Holdings Plc purchased a new position in shares of Repligen in the fourth quarter valued at $202,000. Tower Research Capital LLC TRC increased its position in shares of Repligen by 14.1% in the second quarter. Tower Research Capital LLC TRC now owns 1,448 shares of the biotechnology company’s stock valued at $180,000 after buying an additional 179 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new position in shares of Repligen in the third quarter valued at $169,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Repligen Company Profile
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.